Telix Pharmaceuticals valuation
$13.25Change from previous close: −0.60%Absolute change: −$0.08
Valuation
The P/E ratio is 88.9. The average price target of 11 analysts is $24.17.
Data as of November 17, 2026
Telix Pharmaceuticals compared with similar companies
Telix Pharmaceuticals's P/E (trailing 12 months): 88.9, +27% against the median of a group of 6 similar companies (69.8).
| Metric | Telix Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 88.9 | 69.8 | 44.5 – 95.0 | Middle |
| EV/EBITDA | 69.6 | 69.6 | 32.3 – 140.7 | Middle |
| Price/book | 6.53 | 5.10 | 3.40 – 7.63 | Middle |
| Price/sales | 5.07 | 20.4 | 7.55 – 50.0 | Low |
| Gross margin | 47.6% | 77.3% | 49.8% – 84.4% | Low |
| Operating margin | 6.2% | 14.9% | -12.3% – 23.8% | Middle |
| Net margin | 3.8% | 3.8% | -61.6% – 25.3% | Middle |
| ROE | 7.4% | 10.4% | -1.8% – 35.7% | Middle |
| Debt/equity | 1.19 | 0.16 | 0.05 – 0.41 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $4.52B
- Enterprise value
- $4.86B
- Forward P/E
- -771.4
- EV/revenue
- 5.45
Profitability and growth
- ROA
- 2.7%
- ROIC
- 3.6%
- Revenue growth (year over year)
- 22.3%
- Earnings growth (year over year)
- -1,652.5%
Financial health
- Total cash
- $251.91M
- Total debt
- $579.86M
- Current ratio
- 2.01
- Quick ratio
- 1.74
- Altman Z-Score
- 3.19
- Piotroski F-Score
- 3.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $24.17
- Median price target
- $21.50
- High price target
- $31.50
- Low price target
- $18.80
- Analysts with a price target
- 11
- Consensus
- Buy
- Forward EPS
- -$0.02
- EPS estimate, current year
- $0.07
Shares and trading
- Beta
- 0.63
- Average volume
- 2.17M
- Shares outstanding
- 338.78M
- Float
- 297.96M
- Institutional ownership
- 34.3%
- Insider ownership
- 15.8%
